XML 62 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangibles and Goodwill
3 Months Ended
Oct. 31, 2015
Intangible Assets and Goodwill  
Intangible Assets and Goodwill

Note 8.Intangible Assets and Goodwill

 

Our intangible assets with definite lives consist primarily of customer relationships, technology, brand names, non-compete agreements and patents. These intangible assets are being amortized on the straight-line method over the estimated useful lives of the assets ranging from 3-20 years and have a weighted average amortization period of 12 years. Amortization expense related to intangible assets was $3,094,000 and $2,956,000 for the three months ended October 31, 2015 and 2014, respectively. Our intangible assets that have indefinite useful lives, and therefore are not amortized, consist of trademarks and trade names.

 

The Company’s intangible assets consist of the following:

 

 

 

October 31, 2015

 

 

 

 

 

Accumulated

 

 

 

 

 

Gross

 

Amortization

 

Net

 

Intangible assets with finite lives:

 

 

 

 

 

 

 

Customer relationships

 

$

103,921,000

 

$

(23,590,000

)

$

80,331,000

 

Technology

 

32,885,000

 

(9,081,000

)

23,804,000

 

Brand names

 

6,900,000

 

(2,295,000

)

4,605,000

 

Non-compete agreements

 

3,092,000

 

(1,017,000

)

2,075,000

 

Patents and other registrations

 

2,286,000

 

(808,000

)

1,478,000

 

 

 

 

 

 

 

 

 

 

 

149,084,000

 

(36,791,000

)

112,293,000

 

Trademarks and tradenames

 

7,510,000

 

 

7,510,000

 

 

 

 

 

 

 

 

 

Total intangible assets

 

$

156,594,000

 

$

(36,791,000

)

$

119,803,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

July 31, 2015

 

 

 

 

 

Accumulated

 

 

 

 

 

Gross

 

Amortization

 

Net

 

Intangible assets with finite lives:

 

 

 

 

 

 

 

Customer relationships

 

$

97,697,000

 

$

(39,549,000

)

$

58,148,000

 

Technology

 

26,508,000

 

(12,656,000

)

13,852,000

 

Brand names

 

12,970,000

 

(10,865,000

)

2,105,000

 

Non-compete agreements

 

3,129,000

 

(997,000

)

2,132,000

 

Patents and other registrations

 

2,235,000

 

(788,000

)

1,447,000

 

 

 

 

 

 

 

 

 

 

 

142,539,000

 

(64,855,000

)

77,684,000

 

Trademarks and tradenames

 

8,152,000

 

 

8,152,000

 

 

 

 

 

 

 

 

 

Total intangible assets

 

$

150,691,000

 

$

(64,855,000

)

$

85,836,000

 

 

 

 

 

 

 

 

 

 

 

 

 

Estimated annual amortization expense of our intangible assets for the remainder for fiscal 2016 and the next five years is as follows:

 

Nine month period ending July 31, 2016

 

$

9,716,000 

 

2017

 

12,569,000 

 

2018

 

12,267,000 

 

2019

 

11,943,000 

 

2020

 

10,186,000 

 

2021

 

9,816,000 

 

 

Goodwill changed during fiscal 2015 and the three months ended October 31, 2015 as follows:

 

 

 

 

 

Water

 

 

 

 

 

 

 

 

 

 

 

 

 

Purification

 

Healthcare

 

 

 

 

 

Total

 

 

 

Endoscopy

 

and Filtration

 

Disposables

 

Dialysis

 

Other

 

Goodwill

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, July 31, 2014

 

$

78,274,000

 

$

56,838,000

 

$

81,835,000

 

$

8,133,000

 

$

6,567,000

 

$

231,647,000

 

Acquisitions

 

11,093,000

 

2,965,000

 

6,104,000

 

 

 

20,162,000

 

Foreign currency translation

 

(2,360,000

)

(931,000

)

 

 

(827,000

)

(4,118,000

)

Sale of business

 

 

 

 

 

(5,740,000

)

(5,740,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, July 31, 2015

 

87,007,000

 

58,872,000

 

87,939,000

 

8,133,000

 

 

241,951,000

 

Acquisitions

 

38,973,000

 

 

 

 

 

38,973,000

 

Foreign currency translation

 

(466,000

)

1,000

 

 

 

 

(465,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, October 31, 2015

 

$

125,514,000

 

$

58,873,000

 

$

87,939,000

 

$

8,133,000

 

$

 

$

280,459,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On July 31, 2015, we performed impairment studies of the Company’s goodwill and indefinite lived trademarks and trade names and concluded that such assets were not impaired. While the results of these annual reviews have historically not indicated impairment, impairment reviews are highly dependent on management’s projections of our future operating results and cash flows (which management believes to be reasonable), discount rates based on the Company’s weighted average cost of capital and appropriate benchmark peer companies. Assumptions used in determining future operating results and cash flows include current and expected market conditions and future sales forecasts. Subsequent changes in these assumptions and estimates could result in future impairment. Although we consistently use the same methods in developing the assumptions and estimates underlying the fair value calculations, such estimates are uncertain by nature and can vary from actual results. At July 31, 2015, the fair value of all of our reporting units exceeded book value by substantial amounts, except our Dialysis segment, which had an estimated fair value that exceeded book value by approximately 17%. We believe the most significant assumptions impacting the impairment assessment of our Dialysis segment relate to the assumed projected annual sales and future operating efficiencies included in our projections of future operating results and cash flows of this segment. If future operating results and cash flows are substantially less than our projections, future impairment charges may be recorded. On October 31, 2015, management concluded that no events or changes in circumstances have occurred during the three months ended October 31, 2015 that would indicate that the carrying amount of our intangible assets and goodwill may not be recoverable.